Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
Gratwohl
A
A
Baldomero
H
H
Schwendener
A
A
Gratwohl
M
M
Urbano-Ispizua
A
A
Frauendorfer
K
K
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D001549:Benzamides; D019049:Developed Countries / Q000145:classification / Q000191:economics; D016527:Drug Costs; D005060:Europe / Q000453:epidemiology; D017048:Health Care Costs; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D000068877:Imatinib Mesylate; D007182:Income; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000601:surgery*; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D012955:Societies, Medical / Q000706:statistics & numerical data; D014184:Transplantation, Homologous / Q000191:economics / Q000706:statistics & numerical data
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate